Gemcitabine and cancer of the pancreas: new preparation.  Helpful or not?
(1) The clinical file of gemcitabine in locally advanced metastatic adenocarcinoma of the pancreas mainly comprises one comparative trial versus 5 fluorouracil that shows the superiority of gemcitabine on a mixed end point (pain, functional capacities, weight).  (2) In this trial haematotoxicity (anaemia and neutropenia) and nausea and vomiting were more common on gemcitabine.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D005602:France; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D014481:United States
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D005472:Fluorouracil